PSMA-targeted delivery of docetaxel in prostate cancer using small-sized PDA-based micellar nanovectors

J Control Release. 2025 Mar 10:379:890-905. doi: 10.1016/j.jconrel.2025.01.062. Epub 2025 Jan 30.

Abstract

In this study, we present the first comparative analysis of active and passive drug delivery systems for docetaxel (DTX) in prostate cancer using supramolecular self-assembled micellar nanovectors. Specifically, we developed two novel micelles based on polydiacetylenic amphiphiles (PDA) for passive and active targeting. The active targeting micelles were designed with a prostate-specific membrane antigen (PSMA) ligand, ACUPA, to facilitate recognition by PSMA-positive cancer cells. These PDA-based micelles feature a well-defined structure with a hydrophobic PDA core and a surface functionalized with PEG, and for active targeting, ACUPA. Our micelles demonstrated excellent encapsulation capacity, significantly improving DTX solubility in water, a crucial factor for clinical drug use. In vitro studies confirmed the safety and cytotoxic profiles of both systems, with ACUPA-functionalized micelles showing notable internalization into PSMA-positive LNCaP cells, mediated through the PSMA-ACUPA interaction. In vivo imaging revealed preferential accumulation of ACUPA-functionalized nanomicelles in LNCaP xenograft tumors, suggesting enhanced retention via specific ACUPA-PSMA interactions and active uptake by LNCaP cells. Notably, Balb/c-Foxn1nu/nu early in vivo studies showed a marked reduction in tumor volume and tumor expression levels of proliferation, cell cycle progression, cell survival and anti-apoptotic markers with DTX-loaded micelles functionalized with ACUPA compared to those without ACUPA. Overall, our studies collect initial evidence regarding the feasibility of supramolecular self-assembly of ACUPA-PDA-based nanomicelles for PSMA-targeted drug chemotherapy delivery developments.

Keywords: Active targeting; PSMA; Passive targeting; Prostate cancer; Stable Supramolecular Micelles.

MeSH terms

  • Animals
  • Antigens, Surface* / metabolism
  • Antineoplastic Agents* / administration & dosage
  • Antineoplastic Agents* / pharmacokinetics
  • Antineoplastic Agents* / therapeutic use
  • Cell Line, Tumor
  • Docetaxel* / administration & dosage
  • Docetaxel* / pharmacokinetics
  • Docetaxel* / therapeutic use
  • Drug Delivery Systems
  • Glutamate Carboxypeptidase II* / metabolism
  • Humans
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Micelles
  • Nanoparticles
  • Polymers* / administration & dosage
  • Polymers* / chemistry
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / metabolism
  • Prostatic Neoplasms* / pathology

Substances

  • Docetaxel
  • Micelles
  • Glutamate Carboxypeptidase II
  • Antineoplastic Agents
  • FOLH1 protein, human
  • Antigens, Surface
  • Polymers